Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
isosorbide dinitrate | Tablet, uncoated | 5 mg | Anticipated | Available | Manufacturing | 26/07/2024 |
fluorouracil | Cream | 50 mg/g | Current | Limited Availability | Manufacturing | 26/07/2024 |
gabapentin | Tablet, film coated | 800 mg | Current | Unavailable | Manufacturing | 26/07/2024 |
codeine phosphate hemihydrate~ibuprofen | Tablet, film coated | 12.8 mg~200 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 26/07/2024 |
donepezil hydrochloride | Tablet, film coated | 10 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 26/07/2024 |
levetiracetam | Tablet, film coated | 1000 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 26/07/2024 |
montelukast sodium | Tablet, chewable | 4.16 mg | Resolved | Available | Manufacturing | 26/07/2024 |
betamethasone acetate~betamethasone sodium phosphate | Injection, suspension | 3 mg/mL~3.9 mg/mL | Resolved | Available | Product recall | 26/07/2024 |
gallium (67Ga) citrate | Injection, solution | 74 MBq/mL | Current | Unavailable | Manufacturing | 26/07/2024 |
zolmitriptan | Tablet, film coated | 2.5 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 26/07/2024 |
escitalopram oxalate | Tablet, film coated | 25.47 mg | Current | Unavailable | Manufacturing | 26/07/2024 |
simvastatin | Tablet, film coated | 20 mg | Anticipated | Available | Manufacturing | 26/07/2024 |
fluticasone propionate | Inhalation, pressurised | 125 microgram/actuation | Current | Unavailable | Manufacturing | 26/07/2024 |
tenofovir disoproxil fumarate~emtricitabine | Tablet, film coated | 300 mg~200 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 26/07/2024 |
tadalafil | Tablet, film coated | 5 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 26/07/2024 |
nebivolol hydrochloride | Tablet | 10.9 mg | Anticipated | Available | Manufacturing | 26/07/2024 |
dasatinib | Tablet, film coated | 50 mg | Current | Unavailable | Manufacturing | 26/07/2024 |
dasatinib | Tablet, film coated | 70 mg | Anticipated | Available | Commercial Changes / Commercial viability | 26/07/2024 |
atomoxetine hydrochloride | Capsule, hard | 45.5 mg | Current | Limited Availability | Manufacturing | 26/07/2024 |
cinacalcet hydrochloride | Tablet, film coated | 99 mg | Current | Unavailable | Manufacturing | 26/07/2024 |
cinacalcet hydrochloride | Tablet, film coated | 33 mg | Current | Limited Availability | Manufacturing | 26/07/2024 |
lacosamide | Tablet, film coated | 150 mg | Anticipated | Available | Manufacturing | 26/07/2024 |
risperidone | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 26/07/2024 |
ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~82.725 mg | Current | Unavailable | Manufacturing | 26/07/2024 |
lidocaine hydrochloride | Injection, solution | 400 mg | Current | Unavailable | Manufacturing | 26/07/2024 |
estradiol | Drug delivery system, transdermal | .39 mg | Current | Unavailable | Manufacturing | 26/07/2024 |
lanreotide acetate | Injection, solution | 100 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 26/07/2024 |
doxorubicin hydrochloride | Injection, concentrated | 2 mg/mL | Current | Limited Availability | Manufacturing | 26/07/2024 |
idarubicin hydrochloride | Injection, solution | 1 mg/mL | Resolved | Available | Manufacturing | 26/07/2024 |
duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Anticipated | Available | Manufacturing | 25/07/2024 |
glimepiride | Tablet, uncoated | 3 mg | Resolved | Available | Manufacturing | 25/07/2024 |
anidulafungin | Injection, powder for | 100 mg | Anticipated | Available | Manufacturing | 25/07/2024 |
gabapentin | Tablet, film coated | 600 mg | Anticipated | Available | Manufacturing | 25/07/2024 |
prochlorperazine maleate | Tablet | 5 mg | Current | Unavailable | Manufacturing | 25/07/2024 |
risperidone | Tablet, film coated | 3 mg | Current | Unavailable | Manufacturing | 25/07/2024 |
risperidone | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 25/07/2024 |
risperidone | Tablet, film coated | 2 mg | Current | Unavailable | Manufacturing | 25/07/2024 |
hydrocortisone sodium succinate | Injection, powder for | 334.25 mg | Current | Limited Availability | Manufacturing | 25/07/2024 |
Choriogonadotropin alfa | Injection, solution | 250 microgram | Current | Limited Availability | Unexpected increase in consumer demand | 25/07/2024 |
sildenafil citrate | Tablet, film coated | 28.1 mg | Current | Unavailable | Manufacturing | 25/07/2024 |
duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Resolved | Available | Manufacturing | 25/07/2024 |
duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Resolved | Available | Manufacturing | 25/07/2024 |
cefepime hydrochloride monohydrate | Injection, powder for | 2378.5 mg | Anticipated | Available | Manufacturing | 25/07/2024 |
olmesartan medoxomil | Tablet | 40 mg | Current | Limited Availability | Manufacturing | 25/07/2024 |
ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 25/07/2024 |
latanoprost | Eye Drops, solution | .05 mg/mL | Current | Unavailable | Manufacturing | 25/07/2024 |
lacosamide | Tablet, film coated | 100 mg | Anticipated | Available | Manufacturing | 25/07/2024 |
risperidone | Tablet, film coated | 3 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 25/07/2024 |
risperidone | Tablet, film coated | 4 mg | Current | Unavailable | Manufacturing | 25/07/2024 |
ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~10.341 mg | Current | Limited Availability | Manufacturing | 25/07/2024 |
aciclovir | Injection, solution | 25 mg/mL | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 25/07/2024 |
gliclazide | Tablet, uncoated | 80 mg | Anticipated | Available | Unexpected increase in consumer demand | 25/07/2024 |
larotrectinib sulfate | Oral Liquid, solution | 24.6 mg/mL | Anticipated | Available | Manufacturing | 25/07/2024 |
azithromycin dihydrate | Tablet, film coated | 628.93 mg | Anticipated | Available | Manufacturing | 25/07/2024 |
zoledronic acid monohydrate | Injection, solution | 5.33 mg | Resolved | Available | Manufacturing | 24/07/2024 |
ondansetron hydrochloride dihydrate | Injection, solution | 5 mg | Current | Limited Availability | Manufacturing | 24/07/2024 |
ondansetron hydrochloride dihydrate | Injection, solution | 10 mg | Current | Unavailable | Manufacturing | 24/07/2024 |
hydrocortisone sodium succinate | Injection, powder for | 134 mg | Current | Limited Availability | Manufacturing | 24/07/2024 |
rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 24/07/2024 |
bosentan monohydrate | Tablet, film coated | 129.08 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 24/07/2024 |
cinacalcet hydrochloride | Tablet | 33.064 mg | Current | Unavailable | Manufacturing | 24/07/2024 |
cinacalcet hydrochloride | Tablet | 66.127 mg | Current | Unavailable | Manufacturing | 24/07/2024 |
alfentanil hydrochloride | Injection, solution | 1.09 mg | Current | Limited Availability | Manufacturing | 24/07/2024 |
estradiol | Drug delivery system, transdermal | .78 mg | Current | Unavailable | Manufacturing | 24/07/2024 |
varenicline tartrate~varenicline tartrate | Tablet, film coated | .855 mg~1.71 mg | Resolved | Available | Manufacturing | 24/07/2024 |
rifampicin | Capsule, hard | 150 mg | Current | Unavailable | Manufacturing | 24/07/2024 |
fluoxetine hydrochloride | Capsule, hard | 22.36 mg | Current | Limited Availability | Manufacturing | 24/07/2024 |
doxycycline monohydrate | Tablet, uncoated | 104.1 mg | Current | Limited Availability | Manufacturing | 24/07/2024 |
tobramycin | Inhalation, conventional | 60 mg/mL | Current | Unavailable | Manufacturing | 24/07/2024 |
zolpidem tartrate | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 23/07/2024 |
medroxyprogesterone acetate | Injection, suspension | 150 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 23/07/2024 |
bupivacaine hydrochloride~adrenaline (epinephrine) acid tartrate | Injection, solution | 2.5 mg/mL~4.5 microgram/mL | Resolved | Available | Manufacturing | 23/07/2024 |
perindopril erbumine | Tablet | 8 mg | Current | Unavailable | Manufacturing | 23/07/2024 |
sildenafil citrate | Tablet, film coated | 28.1 mg | Current | Unavailable | Manufacturing | 23/07/2024 |
duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Current | Limited Availability | Manufacturing | 23/07/2024 |
ezetimibe~atorvastatin calcium trihydrate | Tablet, multilayer | 10 mg~10.9 mg | Anticipated | Available | Manufacturing | 23/07/2024 |
vecuronium bromide | Injection, powder for | 10 mg | Resolved | Available | Manufacturing | 23/07/2024 |
oxycodone hydrochloride | Capsule, hard | 10 mg | Current | Unavailable | Commercial Changes / Commercial viability | 23/07/2024 |
melphalan hydrochloride | Injection, powder for | 55.97 mg | Resolved | Available | Manufacturing | 23/07/2024 |
tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 23/07/2024 |
lurasidone hydrochloride | Tablet, film coated | 80 mg | Current | Unavailable | Manufacturing | 23/07/2024 |
lurasidone hydrochloride | Tablet, film coated | 40 mg | Current | Unavailable | Manufacturing | 23/07/2024 |
posaconazole | Tablet, modified release | 100 mg | Resolved | Available | Manufacturing | 23/07/2024 |
levothyroxine sodium | Tablet, uncoated | .1 mg | Current | Unavailable | Manufacturing | 23/07/2024 |
medroxyprogesterone acetate | Injection, suspension | 150 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 23/07/2024 |
minocycline hydrochloride dihydrate | Tablet, film coated | 54 mg | Resolved | Available | Manufacturing | 23/07/2024 |
ezetimibe | Tablet | 10 mg | Current | Limited Availability | Unexpected increase in consumer demand | 23/07/2024 |
framycetin sulfate~dexamethasone~gramicidin | Ear Drops | 5 mg/mL~.5 mg/mL~.05 mg/mL | Current | Unavailable | Manufacturing | 22/07/2024 |
sodium pyrophosphate | Injection, powder for | 30 mg | Resolved | Available | Manufacturing | 22/07/2024 |
vecuronium bromide | Injection, powder for | 10 mg | Resolved | Available | Unexpected increase in consumer demand | 22/07/2024 |
donepezil hydrochloride | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 22/07/2024 |
pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Current | Unavailable | Manufacturing | 22/07/2024 |
pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Manufacturing | 22/07/2024 |
pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Limited Availability | Manufacturing | 22/07/2024 |
latanoprost~timolol maleate | Eye Drops, solution | 50 microgram/mL~6.83 mg/mL | Current | Unavailable | Unexpected increase in consumer demand | 22/07/2024 |
cinacalcet hydrochloride | Tablet | 99.191 mg | Current | Unavailable | Manufacturing | 22/07/2024 |
tadalafil | Tablet, film coated | 20 mg | Resolved | Available | Unexpected increase in consumer demand | 22/07/2024 |
tadalafil | Tablet, film coated | 20 mg | Current | Unavailable | Unexpected increase in consumer demand | 22/07/2024 |
atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 20.681 mg~10 mg | Current | Unavailable | Manufacturing | 22/07/2024 |
morphine sulfate pentahydrate | Capsule, modified release | 30 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 22/07/2024 |
2024年7月29日